Tiziana says nasal MS drug cuts brain inflammation in mid-stage study
Tiziana Life Sciences (TLSA) reported that its nasal MS drug foralumab reduced brain inflammation and was safe in a mid-stage trial for non-active secondary progressive multiple sclerosis. The 50-microgram dose showed a statistically significant reduction in neuroinflammation versus placebo, while both doses improved fatigue scores. The trial was not powered to show definitive clinical changes. The company plans to present detailed results and meet with the FDA.
How this was made
The 30-second read
Why it matters
The data provides the first clinical evidence of neuroinflammation reduction, a key unmet need in MS, potentially de‑risking the program for later‑stage studies.
Market read
First‑report trial data could move TLSA shares and influence the broader neuro‑inflammation biotech space.
What to watch
Regulatory pathway and reimbursement risk remain uncertain despite early biomarker success.
Background
Tiziana Life Sciences (NASDAQ:TLSA) announced its Phase 2a intranasal foralumab trial results in secondary progressive multiple sclerosis.
Ticker impact
Tiziana Life Sciences reported positive Phase 2a data showing its intranasal drug foralumab reduced brain inflammation in secondary progressive MS patients.
upward pressure as the market prices in the favorable neuroinflammation result.
Phase 2a safety and biomarker improvement are material for a biotech with no approved therapy in this indication.
Market effects
May boost sentiment for neuro‑inflammation and MS‑focused biotech stocks.
US biotech market could see modest gains.
Positive data could attract interest from global investors tracking CNS therapeutics.
Counterpoint
The trial size is small and the 100‑µg dose failed to show significance, suggesting limited efficacy.
Key entities
- companyTiziana Life Sciences Ltd
Biotech developing intranasal foralumab for MS.
- personIvor Elrifi
CEO of Tiziana Life Sciences.
